{"id":21054,"date":"2022-04-01T09:41:58","date_gmt":"2022-04-01T07:41:58","guid":{"rendered":"https:\/\/idibell.cat\/?p=21054"},"modified":"2022-04-01T09:53:57","modified_gmt":"2022-04-01T07:53:57","slug":"la-inhibicio-farmacologica-duna-proteina-redueix-les-metastasis-en-models-in-vivo-i-in-vitro-de-sarcoma-dewing","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/04\/la-inhibicio-farmacologica-duna-proteina-redueix-les-metastasis-en-models-in-vivo-i-in-vitro-de-sarcoma-dewing\/","title":{"rendered":"La inhibici\u00f3 farmacol\u00f2gica d&#8217;una prote\u00efna redueix les met\u00e0stasis en models in vivo i in vitro de sarcoma d&#8217;Ewing"},"content":{"rendered":"<p>Un <a href=\"https:\/\/www.nature.com\/articles\/s41388-022-02279-w\">estudi<\/a> amb participaci\u00f3 del grup de recerca a Sarcomes de l&#8217;IDIBELL, i liderat pel grup de Patologia Molecular dels Sarcomes de l\u2019Institut de Biomedicina de Sevilla (IBiS) ha descrit que la prote\u00efna G9a estaria associada al desenvolupament de met\u00e0stasi al Sarcoma d&#8217;Ewing , de manera que <strong>la sobreexpressi\u00f3 d&#8217;aquesta prote\u00efna indicaria un pron\u00f2stic advers dels pacients<\/strong>. G9a \u00e9s un enzim que modifica els senyals epigen\u00e8tics de l&#8217;ADN, aquells que activen i inactiven la transcripci\u00f3 de gens.<\/p>\n<p>El <strong>Sarcoma d&#8217;Ewing<\/strong> \u00e9s un tumor maligne de c\u00e8l\u00b7lules rodones, fonamentalment pedi\u00e0tric que \u00e9s considerat una malaltia rara en la qual les c\u00e8l\u00b7lules neopl\u00e0siques se situen a l&#8217;os o en teixits tous. El 80% dels pacients amb malaltia lliure de met\u00e0stasi supera la malaltia amb el tractament est\u00e0ndard, per\u00f2 en els pacients que desenvolupen met\u00e0stasi el percentatge es redueix al 20-30%. Per tant, els esfor\u00e7os en recerca se centren a buscar alternatives terap\u00e8utiques que evitin el desenvolupament de met\u00e0stasi o puguin incrementar la superviv\u00e8ncia dels pacients.<\/p>\n<p>En aquest estudi precl\u00ednic, els investigadors proposen una alternativa per disminuir el desenvolupament de met\u00e0stasi en aquests pacients utilitzant un f\u00e0rmac, anomenat BIX01294, que inhibeix l&#8217;activitat de la prote\u00efna G9a. L&#8217;estudi ha <strong>demostrat la disminuci\u00f3 significativa de la proliferaci\u00f3 cel\u00b7lular <\/strong>i de diversos processos involucrats en el desenvolupament metast\u00e0tic in vitro (migraci\u00f3, adhesi\u00f3, invasi\u00f3 i capacitat clonog\u00e8nica) despr\u00e9s del tractament amb BIX01294. A m\u00e9s, BIX01294 va alentir el creixement del tumor primari i va reduir el desenvolupament de met\u00e0stasi en m\u00e9s d&#8217;un 40% en dos models de ratol\u00ed.<\/p>\n<p>Aquest treball avalaria realitzar <strong>futurs assajos cl\u00ednics en pacients en qu\u00e8 BIX01294 podria complementar la ter\u00e0pia est\u00e0ndard de pacients amb Sarcoma de Ewing<\/strong>, amb \u00e8xit per als que no presenten met\u00e0stasi, per\u00f2 que necessita millorar la capacitat d&#8217;inhibir aquest factor amb valor pron\u00f2stic advers, comenten els investigadors.<\/p>\n<p>En aquest treball tamb\u00e9 hi han participat l&#8217;Hospital Sant Joan de D\u00e9u, l&#8217;Institut de Parasitologia i Biomedicina L\u00f3pez-Neyra, la divisi\u00f3 de c\u00e0ncer de l&#8217;Imperial College de Londres i el Centre de Recerca de Biomedicina a la Xarxa (CIBERONC). L&#8217;estudi ha estat finan\u00e7at gr\u00e0cies a un ajut a grups cooperatius de l&#8217;Associaci\u00f3 Espanyola Contra el C\u00e0ncer i a dos projectes finan\u00e7ats per l&#8217;Institut de Salut Carlos III (PI17\/0464, PI20\/0003), aix\u00ed com al projecte de recerca de la Conselleria de Salut de la Junta d&#8217;Andalusia (PI-0013-2018).<\/p>\n<p>Text adaptat de l&#8217;Institut de Biomedicina de Sevilla (IBiS): <a href=\"https:\/\/www.ibis-sevilla.es\/agenda\/noticias\/2022\/03\/investigadores-del-instituto-de-biomedicina-de-sevilla-describen-una-proteina-epigenetica-asociada-al-proceso-metastasico-en-sarcoma-de-ewing.aspx\">enlla\u00e7<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;enzim G9a augmenta la probabilitat de desenvolupar met\u00e0stasi en aquestes neopl\u00e0sies d&#8217;os o teixits tous, per\u00f2 el tractament amb el seu inhibidor (BIX01294) podria millorar el control de la met\u00e0stasi en els pacients.<\/p>\n","protected":false},"author":8,"featured_media":21055,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,398],"tags":[],"class_list":["post-21054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-sarcoma"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 09:59:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21054"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21054\/revisions"}],"predecessor-version":[{"id":21058,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21054\/revisions\/21058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21055"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}